Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 27;23(3):202–206. doi: 10.1055/s-0044-1778708

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ )

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Pre- and post-treatment fluorodeoxyglucose positron emission tomography (PET) at first presentation showing complete metabolic response of primary right lung, nodal metastasis and left pleural effusion. ( A ). Pre-therapy maximum intensity projection (MIP) image showing right lung primary tumor and mediastinal nodal metastasis. ( B – D ) Pre-therapy transverse section of PET, computed tomography (CT), and fused images, respectively, showing the lung ( red arrows ) and nodal metastasis ( orange arrows ). ( E – G ) Post-therapy transverse section of PET, CT, and fused images, respectively, showing complete resolution of primary lung and nodal disease. ( H ) Post-therapy MIP image showing complete metabolic response. There was no evidence of FDG-avid local lung carcinoma recurrence or extra peritoneal spread. This led to a change to a 3rd line regimen which consisted of Carboplatin (AUC5), pemetrexed, atezolizumab, bevacizumab. Three months later 18F-FDG PET/CT showed excellent response with complete metabolic remission and no evidence of residual or new FDG-avid malignant or metastatic disease.